Trial Profile

A prospective study investigating whether -2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) findings after molecular targeted therapy can predict the OS of patients with metastatic renal cell carcinoma who are treated by sequential molecular targeted therapies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Everolimus (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com